Greg Mayes, Antios Therapeutics CEO
Antios' HBV collab axed after clinical hold, but biotech believes safety incident is not treatment-related
The FDA has placed a clinical hold on a Phase IIa study of Antios Therapeutics’ investigational hepatitis B med, CEO Greg Mayes confirmed to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
